Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index; 42 of the 115 sources its claims cite were checked for support.

Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring

Open access
Klonoff, David C., Gabbay, Monica, Moon, Sun Joon, Wilmot, Emma G. · 2025 · Journal of Diabetes Science and Technology

Abstract

Continuous glucose monitoring (CGM) has been shown to improve glycemic control and self-monitoring, as well as to reduce the risk of hypoglycemia. Integrated CGM (iCGM) FDA-cleared systems with published performance data are established nonadjunctive and accurate CGM tools that can directly inform decision-making in the treatment of diabetes (i.e., insulin dosing). Studies have assessed accuracy and safety data of CGMs that were eventually cleared for iCGM by the FDA and that informed the recommendation for their nonadjunctive use. Subsequent robust clinical trials and real-world studies demonstrated clinical effectiveness with improvements in a range of patient outcomes. In recent years, a number of non-iCGM-approved CGM devices have entered the market outside the United States worldwide. Some of these non-iCGM-approved CGM devices require additional user verification of blood glucose levels to be performed for making treatment decisions, termed adjunctive. Moreover, in many non-iCGM-approved CGM devices, accuracy studies published in peer-reviewed journals are scarce or have many limitations. Consequently, non-iCGM-approved CGM devices cannot be automatically perceived as having the same performance or quality standards than those approved for iCGM by the FDA. As a result, although these devices tend to cost less than iCGMs that carry FDA clearance and could therefore be attractive from the point of view of a health care payer, it must be emphasized that evaluation of costs should not be limited to the device (such as the usability preference that patients have for nonadjunctive sensors compared to adjunctive sensors) but to the wider value of the total benefit that the product provides to the patient.

Overview

CoChat Summary

TL;DR

This review argues that FDA-cleared integrated continuous glucose monitoring (iCGM) systems meet the strictest accuracy standard and should be distinguished from non-iCGM-approved devices marketed outside the United States. It contends that non-iCGM devices often lack robust published accuracy and outcome evidence, may require adjunctive blood glucose confirmation, and should not be assumed equivalent based on lower cost alone.

Key findings

  • FDA iCGM special controls are described as the strictest CGM accuracy standard worldwide; the paper lists Abbott FreeStyle Libre 2, Libre 2 Plus, Libre 3, Libre 3 Plus, Dexcom G6, and Dexcom G7 as meeting iCGM requirements, with an addendum noting later iCGM designation for Senseonics Eversense.
  • Table 1 iCGM performance requirements include, for example, lower one-sided 95% confidence bounds exceeding 85% for readings within ±15 mg/dL when <70 mg/dL, exceeding 70% for within ±15% when 70–180 mg/dL, exceeding 80% for within ±15% when >180 mg/dL, and exceeding 87% for within ±20% across the measuring range.
  • Non-iCGM-approved devices outside the United States may have scarce or limited peer-reviewed accuracy studies; cited limitations include small samples (e.g., n < 100), high proportions of type 2 diabetes, adult-only studies despite indicated ages ≥2 years, few data in the critical <70 mg/dL range, and no glucose or insulin challenges.
  • Cost comparisons should include total value—transmitters, readers, additional fingerstick tests, support services, and digital data security—not just device price; many non-iCGM-approved devices may be cheaper but are said to come up short in ease of use, technical performance, and manufacturer support.

Methods

  • Narrative review comparing FDA iCGM special control performance requirements with quality standards of CGM systems, particularly non-iCGM-approved devices that entered markets outside the United States.
  • Sources include FDA classification documents, Table 1 iCGM special controls, published accuracy studies, regulatory summaries, and prior reviews by Pemberton et al. and Freckmann et al.; no primary patient data or systematic search strategy is described.
  • Main analysis is a narrative synthesis with tables summarizing iCGM performance requirements and FDA nonadjunctive CGM definitions alongside limitations of accuracy studies for non-iCGM-approved devices.

Limitations

  • The paper does not explicitly state limitations.
  • Evident: it is a narrative review without a described systematic search, formal risk-of-bias assessment, or meta-analysis, so selection of cited evidence may be selective.
  • Evident: the comparison relies on FDA iCGM criteria and published/regulatory documents rather than independent primary accuracy testing of the devices discussed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/19322968241250357

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 1 Not valid · 18 Not checked · 11 Own results and interpretations

20 more claims

Create a free account to see all 44 claims and to verify the 73 references still open.

See all claims — free account
  • It may state two separate claims as one. 17
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 44

Metadata

Authors
Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G.
Affiliations
  • Diabetes Research Institute, Mills-Península Medical Center, San Mateo, CA, USA
  • UNIFESP—Federal University of Sao Paulo, Sao Paulo, Brazil
  • Kangbuk Samsung Hospital (KR)
  • University of Nottingham (GB)
Corresponding author
Klonoff, David C.
Venue
Journal of Diabetes Science and Technology
Published
2024-05-03
Volume
19
Issue
5
Pages
1392-1399
ISSN
1932-2968 (ISSN-L)
OpenAlex
W4396592970
Cited by
36
References
45
Citations by year
2026: 19 · 2025: 14 · 2024: 3
FWCI
2.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Diabetes Science and Technology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
Funders
Abbott Diabetes Care
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
continuous glucose monitoring, FDA clearance, CGM accuracy, diabetes management, insulin dose, hypoglycemia prevention, glycemic control, cost-effectiveness
MeSH terms
Continuous Glucose Monitoring, Blood Glucose, Diabetes Mellitus, Humans, United States, United States Food and Drug Administration, Blood Glucose Self-Monitoring, Device Approval

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring. https://app.cochat.ai/papers/10.1177/19322968241250357
The paper
Klonoff, D. C., Gabbay, M., Moon, S. J., & Wilmot, E. G. (2025). Importance of FDA-Integrated Continuous Glucose Monitors to Ensure Accuracy of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968241250357

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.